Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | July 24, 2026

Jul 24, 2026

•

3 min read

Biotech & Pharma Updates | July 24, 2026

🧬 Scribe Therapeutics raises nearly $129M IPO, advancing gene editing and ASCVD therapy development, Amgen submits data package to FDA seeking hearing to defend Tavneos' U.S. market status, FDA panel endorses lifting restrictions on four peptides for compounding pharmacies use

Christian Cuchapin, +1

Biotech & Pharma Updates | July 23, 2026

Jul 23, 2026

•

3 min read

Biotech & Pharma Updates | July 23, 2026

🧬 Eli Lilly's (retatrutide) hits Ph3 primary endpoints with 22.6% weight loss in obesity with cardiovascular disease, J&J's Tecvayli (teclistamab) and Talvey (talquetamab) combo cuts multiple myeloma progression risk 89% in Ph3, GSK's Jideytro (zidesamtinib) wins FDA approval for ROS1-positive metastatic non-small cell lung cancer

Christian Cuchapin, +1

Biotech & Pharma Updates | July 22, 2026

Jul 22, 2026

•

3 min read

Biotech & Pharma Updates | July 22, 2026

🧬 Repligen to acquire BioLife Solutions for $1.5B, securing critical cryopreservation media for cell therapy market, Novartis to invest $95M in South Korea to expand radioligand therapy supply chain ecosystem, Crystalys Therapeutics raises $130M Series B to advance gout drug dotinurad through Phase 3

Christian Cuchapin, +1

Biotech & Pharma Updates | July 21, 2026

Jul 21, 2026

•

3 min read

Biotech & Pharma Updates | July 21, 2026

🧬 Bristol Myers Squibb, Nvidia expand AI collaboration to build “most powerful” life sciences AI infrastructure, Gilead Sciences, Merck & Co.'s (islatravir/lenacapavir) Ph3 data support first weekly oral human immunodeficiency virus treatment, Tempus AI to acquire Personalis for $1.5B, expanding cancer MRD diagnostics portfolio

Christian Cuchapin, +1

Biotech & Pharma Updates | July 20, 2026

Jul 20, 2026

•

3 min read

Biotech & Pharma Updates | July 20, 2026

🧬 Samsung Biologics launches all-cash tender offer to acquire PolyPeptide for ~CHF 1.46B ($1.81B), expanding peptide CDMO capabilities, UK biotech financing hits five-year high with £2.11B ($2.84B) equity investment in Q2 2026, Scribe Therapeutics plans $96M IPO to advance lipid-lowering CRISPR genetic medicines

Christian Cuchapin, +1

Biotech & Pharma Updates | July 17, 2026

Jul 17, 2026

•

3 min read

Biotech & Pharma Updates | July 17, 2026

🧬 Jasper Therapeutics merges with Kira Pharmaceuticals, gaining differentiated complement portfolio including dual-inhibitor KP-104, Takeda's (zasocitinib) clears scalp psoriasis in 75% of patients in Ph3 moderate-to-severe plaque psoriasis trials, Novartis' Fabhalta (iptacopan) receives FDA traditional approval to slow kidney function decline in primary immunoglobulin A nephropathy

Christian Cuchapin, +1

Biotech & Pharma Updates | July 16, 2026

Jul 16, 2026

•

3 min read

Biotech & Pharma Updates | July 16, 2026

🧬 FDA approves Merck & Co.'s Lipfendra (enlicitide), first oral PCSK9 inhibitor pill, for hypercholesterolemia including heterozygous familial hypercholesterolemia, Eli Lilly to acquire AtaiBeckley for up to $3.8B, marking pharma's first psychedelics push into depression treatment, Johnson & Johnson raises 2026 guidance as Tremfya hits $2B and Icotyde launch exceeds expectations

Christian Cuchapin, +1

Biotech & Pharma Updates | July 15, 2026

Jul 15, 2026

•

3 min read

Biotech & Pharma Updates | July 15, 2026

🧬 FDA approves Celcuity's Revtorpyk (gedatolisib) for PI3K pathway hormone receptor-positive, HER2-negative metastatic breast cancer after Ph3 success, Insilico Medicine, Bora Pharmaceuticals partner on AI drug discovery and commercialization, deal worth $2.5B, Kelun-Biotech's (sacituzumab tirumotecan) plus Merck & Co.'s Keytruda meets primary endpoint in Ph3 for PD-L1-negative non-squamous non-small cell lung cancer

Christian Cuchapin, +1

Biotech & Pharma Updates | July 14, 2026

Jul 14, 2026

•

3 min read

Biotech & Pharma Updates | July 14, 2026

🧬 Biogen's (diranersen) Ph2 results show tau-targeting antisense oligonucleotide slows decline in Alzheimer's disease, AstraZeneca, Dizal Pharmaceutical strike exclusive global lung cancer license deal, $600M upfront, up to $1.5B total, Biogen, Eisai win FDA approval for subcutaneous Leqembi (lecanemab) initiation therapy in Alzheimer's disease

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | July 24, 2026

Biotech & Pharma Updates | July 23, 2026

Biotech & Pharma Updates | July 22, 2026

Biotech & Pharma Updates | July 21, 2026

Biotech & Pharma Updates | July 20, 2026

Biotech & Pharma Updates | July 17, 2026

Biotech & Pharma Updates | July 16, 2026

Biotech & Pharma Updates | July 15, 2026

Biotech & Pharma Updates | July 14, 2026

TLDR Biotech

FAQ

Media Partners